Novo Nordisk A/S is a biotechnology business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Novo Nordisk A/S employs 59,337 staff and has a trailing 12-month revenue of around $201.3 billion.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $91.30 |
|---|---|
| 52-week range | $93.82 - $201.76 |
| 50-day moving average | $176.81 |
| 200-day moving average | $157.37 |
| Wall St. target price | $154.71 |
| PE ratio | 43.6005 |
| Dividend yield | $7.075 (1.08%) |
| Earnings per share (TTM) | $4.28 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $91.3 from 2023-09-22
| 1 week (2023-09-18) | -51.07% |
|---|---|
| 1 month (2023-08-25) | -51.03% |
| 3 months (2023-06-23) | -42.60% |
| 6 months (2023-03-24) | -40.23% |
| 1 year (2022-09-23) | -6.77% |
|---|---|
| 2 years (2021-09-24) | -9.33% |
| 3 years (2020-09-25) | 34.82% |
| 5 years (2018-09-25) | 102.22% |
Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $201.3 billion |
|---|---|
| Operating margin TTM | 43.2% |
| Gross profit TTM | $148.5 billion |
| Return on assets TTM | 21.76% |
| Return on equity TTM | 81.54% |
| Profit margin | 33.4% |
| Book value | $2.52 |
| Market Capitalization | $834.9 billion |
TTM: trailing 12 months
Dividend payout ratio: 5.34% of net profits
Recently Novo Nordisk A/S has paid out, on average, around 5.34% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.08% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 1.08% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $7.075 per share.
While Novo Nordisk A/S's payout ratio might seem low, this can signify that Novo Nordisk A/S is investing more in its future growth.
Novo Nordisk A/S's most recent dividend payout was on 28 August 2023. The latest dividend was paid out to all shareholders who bought their shares by 17 August 2023 (the "ex-dividend date").
Novo Nordisk A/S's shares were split on a 2:1 basis on 19 September 2023. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.
Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $93.8191 up to $201.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.2421. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc. ; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.